Agenus Inc (AGEN) stock
AGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.21−0.08 (-1.27%)
Close on Nov 17, 2026Market cap $279.58MP/E –Yield –
Agenus operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Agenus's operating income for the twelve months ending Jun 30, 2026 was $36.20M. For fiscal 2025 it was -$20.17M. The highest annual figure on record is $25.75M in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$20.17M | – |
| FY2024 | Dec 31, 2024 | -$120.48M | – |
| FY2023 | Dec 31, 2023 | -$159.55M | – |
| FY2022 | Dec 31, 2022 | -$179.43M | -796.9% |
| FY2021 | Dec 31, 2021 | $25.75M | – |
| FY2020 | Dec 31, 2020 | -$117.24M | – |
| FY2019 | Dec 31, 2019 | -$70.14M | – |
| FY2018 | Dec 31, 2018 | -$123.82M | – |
| FY2017 | Dec 31, 2017 | -$103.80M | – |
| FY2016 | Dec 31, 2016 | -$107.48M | – |
| FY2015 | Dec 31, 2015 | -$80.70M | – |
| FY2014 | Dec 31, 2014 | -$43.32M | – |
| FY2013 | Dec 31, 2013 | -$24.98M | – |
| FY2012 | Dec 31, 2012 | -$6.74M | – |
| FY2011 | Dec 31, 2011 | -$19.09M | – |
| FY2010 | Dec 31, 2010 | -$21.75M | – |
| FY2009 | Dec 31, 2009 | -$27.68M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $11.29M | – |
| Q1 FY2026 | Mar 31, 2026 | $15.05M | – |
| Q4 FY2025 | Dec 31, 2025 | $14.40M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.55M | – |
| Q2 FY2025 | Jun 30, 2025 | -$16.71M | – |
| Q1 FY2025 | Mar 31, 2025 | -$13.31M | – |
| Q4 FY2024 | Dec 31, 2024 | -$25.90M | – |
| Q3 FY2024 | Sep 30, 2024 | -$31.50M | – |
| Q2 FY2024 | Jun 30, 2024 | -$30.19M | – |
| Q1 FY2024 | Mar 31, 2024 | -$32.88M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.20M | – |
| Q3 FY2023 | Sep 30, 2023 | -$46.34M | – |
| Q2 FY2023 | Jun 30, 2023 | -$54.67M | – |
| Q1 FY2023 | Mar 31, 2023 | -$54.34M | – |
| Q4 FY2022 | Dec 31, 2022 | -$57.76M | – |
| Q3 FY2022 | Sep 30, 2022 | -$41.65M | -122.2% |
| Q2 FY2022 | Jun 30, 2022 | -$44.57M | – |
| Q1 FY2022 | Mar 31, 2022 | -$35.46M | – |
| Q4 FY2021 | Dec 31, 2021 | -$54.03M | – |
| Q3 FY2021 | Sep 30, 2021 | $187.54M | – |
| Q2 FY2021 | Jun 30, 2021 | -$66.40M | – |
| Q1 FY2021 | Mar 31, 2021 | -$41.37M | – |
| Q4 FY2020 | Dec 31, 2020 | -$21.71M | – |
| Q3 FY2020 | Sep 30, 2020 | -$34.79M | – |
| Q2 FY2020 | Jun 30, 2020 | -$33.27M | – |
| Q1 FY2020 | Mar 31, 2020 | -$27.46M | -204.8% |
| Q4 FY2019 | Dec 31, 2019 | -$19.28M | – |
| Q3 FY2019 | Sep 30, 2019 | -$35.92M | – |
| Q2 FY2019 | Jun 30, 2019 | -$41.15M | – |
| Q1 FY2019 | Mar 31, 2019 | $26.21M | – |
| Q4 FY2018 | Dec 31, 2018 | -$39.43M | – |
| Q3 FY2018 | Sep 30, 2018 | -$26.08M | – |
| Q2 FY2018 | Jun 30, 2018 | -$16.57M | – |
| Q1 FY2018 | Mar 31, 2018 | -$41.75M | – |
| Q4 FY2017 | Dec 31, 2017 | -$29.99M | – |
| Q3 FY2017 | Sep 30, 2017 | -$31.66M | – |
| Q2 FY2017 | Jun 30, 2017 | -$28.89M | – |
| Q1 FY2017 | Mar 31, 2017 | -$13.26M | – |
| Q4 FY2016 | Dec 31, 2016 | -$19.68M | – |
| Q3 FY2016 | Sep 30, 2016 | -$36.22M | – |
See a number that looks wrong?